Vizora日本語

EisaiEisai Co., Ltd.4523東証プライム医薬品FY ending Mar 2024, consolidated, IFRS

Eisai FY ending Mar 2024 results

Eisai brought in ¥741.8B in revenue.

Out of every ¥100 of sales, about ¥7 is left as operating profit.

Revenue changed -0.4% from the prior year, operating profit +33.4%.

Revenue and profit pattern

Revenue down, profit up

Revenue -0.4% · profit +33.4%, calculated from disclosed figures.

Operating leverage: -93.75× (profit growth ÷ revenue growth)

What changed from last year

FY ending Mar 2023 → FY ending Mar 2024

Revenue
-0.4%¥744.4B → ¥741.8B
Operating income
+33.4%¥40B → ¥53.4B
Net income attributable to owners
-23.5%¥55.4B → ¥42.4B
Operating cash flow
Back to profit-¥1.77B → ¥56B

Results at a glance

  • Sales stood still in FY ending Mar 2024 at ¥741.8B (-0.4%), but the profit lines split apart.
  • Operating income rose from ¥40B to ¥53.4B (+33.4%). Net income did the opposite, sliding from ¥55.4B to ¥42.4B (-23.5%).
  • Cash from operations turned around too: an outflow of -¥1.77B the year before became an inflow of ¥56B.

Things to watch

  • Once patents or data protection lapse on drugs such as Lenvima, generics can move in and sales can fall fast.
  • Eisai already cut prices in China to get Lenvima onto the reimbursement list and when Methycobal fell under central purchasing; along with Japan's regular price cuts, this could happen again.
  • A disagreement with a partner like Merck & Co. over contract terms could end the alliance.

Annual securities report (114th term) / 事業等のリスク · Annual securities report (114th term) / 経営方針、経営環境及び対処すべき課題等

Where the money goes

FY ending Mar 2023 → FY ending Mar 2024

※ Cost of revenue is not disclosed; expenses are combined

Where ¥100 of sales goes

For every ¥100 Eisai sells, how much goes where, and how much is kept.

FY ending Mar 2024
Operating costs
¥93
Operating profit
¥7
Net profit kept
¥6

Annual margin trends

Operating margin7.2%
FY ending Mar 2017: 11.0%11.0%FY ending Mar 2018: 12.9%12.9%FY ending Mar 2019: 13.4%13.4%FY ending Mar 2022: 7.1%7.1%FY ending Mar 2023: 5.4%5.4%FY ending Mar 2024: 7.2%7.2%FY17FY18FY19FY22FY23FY24
Net margin5.7%
FY ending Mar 2017: 7.3%7.3%FY ending Mar 2018: 8.6%8.6%FY ending Mar 2019: 9.9%9.9%FY ending Mar 2022: 6.3%6.3%FY ending Mar 2023: 7.4%7.4%FY ending Mar 2024: 5.7%5.7%FY17FY18FY19FY22FY23FY24

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (4)

  • EDINET (FSA Japan)

    有価証券報告書－第114期(2025/04/01－2026/03/31)

    ID S100YB052026-06-12Open

  • EDINET (FSA Japan)

    有価証券報告書－第111期(2022/04/01－2023/03/31)

    ID S100R09Z2023-06-21Open

  • EDINET (FSA Japan)

    有価証券報告書－第110期(令和3年4月1日－令和4年3月31日)

    ID S100O9U72022-06-17Open

  • EDINET (FSA Japan)

    有価証券報告書－第109期(令和2年4月1日－令和3年3月31日)

    ID S100LKNM2021-06-18Open

Extracted from XBRL: 11 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image